论文部分内容阅读
目的观察桂哌齐特对急性脑梗死病人血清基质金属蛋白酶9(MMP-9)和超敏血清C-反应蛋白(hs-CRP)的影响。方法急性脑梗死病人124例,随机分为2组(均n=62):桂哌齐特组[桂哌齐特(240mg·d-1,iv,gtt)+常规治疗]、对照组(常规治疗)。同时设立健康组30例。分别检测2组病人治疗前、治疗后d5和d14和健康组的MMP-9和hs-CRP水平。治疗前和治疗后d14对2组病人进行改良爱丁堡+斯堪的那维亚脑卒中评分量表(MESSS)及日常生活能力Barthel指数(BI)评分。结果与健康组比较,所有病人MMP-9和hs-CRP的水平明显增高(P<0.01);与对照组比较,桂哌齐特组治疗后d14的MMP-9水平、hs-CRP水平和MESSS评分显著下降(P<0.01),BI显著增高(P<0.01)。结论桂哌齐特可降低急性脑梗死病人的MMP-9和hs-CRP水平,改善预后。
Objective To observe the effects of cinepazide on the serum levels of matrix metalloproteinase 9 (MMP-9) and hs-CRP in patients with acute cerebral infarction. Methods A total of 124 patients with acute cerebral infarction were randomly divided into 2 groups (n = 62 each): Cinepazide (240 mg · d-1, iv, gtt) + conventional treatment; treatment). At the same time the establishment of health group 30 cases. The levels of MMP-9 and hs-CRP in two groups of patients before treatment, d5 and d14 after treatment, and healthy group were detected. Before and after treatment d14 improved the two groups of patients Edinburgh Scandinavia Stroke Scale (MESSS) and daily living ability Barthel Index (BI) score. Results Compared with the healthy group, the levels of MMP-9 and hs-CRP in all patients were significantly increased (P <0.01). Compared with the control group, the levels of MMP-9, hs-CRP and MESSS The score decreased significantly (P <0.01), BI significantly increased (P <0.01). Conclusion Cinepazide can reduce the levels of MMP-9 and hs-CRP in patients with acute cerebral infarction and improve the prognosis.